Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Early Phase 1
4(100.0%)
4Total
Early Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06104241Early Phase 1Recruiting

BGT007 Cells for the Treatment of Refractory Digestive System Tumors

Role: collaborator

NCT06104215Early Phase 1Recruiting

BGT007H Cells for the Treatment of Refractory Digestive System Tumors

Role: collaborator

NCT05654077Early Phase 1Unknown

EBV CAR-T Cells for Nasopharyngeal Carcinoma

Role: collaborator

NCT05616468Early Phase 1Unknown

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Role: collaborator

All 4 trials loaded